Did you know that there are approximately 12 million people living with autosomal dominant polycystic kidney disease worldwide? Today, on PKD Awareness Day, our team is taking the time to recognize those living with PKD, including #ADPKD, and their caregivers as we continue to advance our potential treatment, RGLS8429, through the clinic. ? #endPKD #PKDAwarenessDay
关于我们
Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is located in San Diego, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.
- 网站
-
https://www.regulusrx.com
Regulus Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 创立
- 2007
- 领域
- microRNA和great company culture
地点
-
主要
获取路线
US，CA，San Diego，92121
Regulus Therapeutics员工
动态
-
Catch our team at both the Wells Fargo Healthcare and H.C. Wainwright & Co., LLC Global Investors Conferences this month! If you’re attending, come listen to one of our presentations to learn more about our ongoing work in autosomal dominant polycystic kidney disease. ?#ADPKD?
-
-
Today we announced our second quarter financial results and recent updates. Read more: https://lnkd.in/ej8swmMn $RGLS
-
-
Our team’s headed to Boston next week for Canaccord Genuity Group Inc.'s 44th Annual Growth Conference. To learn more about Regulus and our work in autosomal dominant polycystic kidney disease, check out our presentation at 8:30am ET on Tuesday, August 13th. We hope to see you there! #ADPKD
-
-
Members of our leadership team are looking forward to presenting at both the H.C. Wainwright & Co., LLC Third Annual Kidney Virtual Conference and JonesTrading’s JonesHealthcare Seaside Summit next week! During the presentations, the team will share new analyses from the third cohort of patients in our ongoing Phase 1b trial of RGLS8429 for those living with #ADPKD. Learn more: https://lnkd.in/e5K2FXsy
-
-
Today our Associate Director of Translational Medicine Tania Valencia is presenting at the ProteiNext 2024: Extracellular Vesicles Symposium! If you’re attending, be sure to check out her session, “Urinary Exosomal Polycystins as Biomarkers for Autosomal Dominant Polycystic Kidney Disease”, on Wednesday, June 12 at 3:25pm ET. Learn more and register for the event here: https://lnkd.in/ejFswwzU
-
-
Members of our team are excited to be in Stockholm this week for the European Renal Association (ERA) Congress and look forward to meeting with and learning from peers in the #nephrology space. If you’re interested in hearing more about Regulus’ work in kidney diseases, including autosomal dominant polycystic kidney disease, please reach out, we’d love to connect! #ERA24 #ADPKD
-
-
Today is International Clinical Trials Day and our team is taking the day to recognize the individuals who participate in and facilitate clinical trials, both in our work in autosomal dominant polycystic kidney disease here at Regulus and all trials around the world. Thank you! #ClinicalTrialsDay #CTD2024 #ADPKD
-
-
Today we announced our first quarter financial results and recent updates. Read more: https://lnkd.in/eBSpXKj5 $RGLS
-